Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.

Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE.

Oncogenesis. 2018 Feb 28;7(2):23. doi: 10.1038/s41389-017-0015-5.


Development of new preclinical models to advance adrenocortical carcinoma research.

Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME.

Endocr Relat Cancer. 2018 Apr;25(4):437-451. doi: 10.1530/ERC-17-0447. Epub 2018 Jan 25.


Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.

Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE.

Oncotarget. 2017 Aug 24;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28.


Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.

Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR.

Oncotarget. 2016 Aug 9;7(32):51619-51625. doi: 10.18632/oncotarget.10010.


FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.

Kessler BE, Sharma V, Zhou Q, Jing X, Pike LA, Kerege AA, Sams SB, Schweppe RE.

Mol Cancer Res. 2016 Sep;14(9):869-82. doi: 10.1158/1541-7786.MCR-16-0007. Epub 2016 Jun 3.


The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE.

Mol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24.


Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.

Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE.

Oncotarget. 2015 Apr 30;6(12):10175-94.


Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.

Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE.

Horm Cancer. 2015 Jun;6(2-3):87-99. doi: 10.1007/s12672-015-0219-0. Epub 2015 Mar 24.


Development and characterization of six new human papillary thyroid carcinoma cell lines.

Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL.

J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. doi: 10.1210/jc.2014-2624. Epub 2014 Nov 26.


Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8.

Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1436-44. doi: 10.1210/jc.2013-3636. Epub 2014 Apr 23.


mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.

Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1368-75. doi: 10.1210/jc.2014-1171. Epub 2014 Apr 8.


Thyroid cancer cell line misidentification: an update.

Schweppe RE.

J Clin Endocrinol Metab. 2013 Mar;98(3):956-7. doi: 10.1210/jc.2012-4182. No abstract available.


Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.

Schweppe RE.

Front Endocrinol (Lausanne). 2012 Jun 19;3:81. doi: 10.3389/fendo.2012.00081. eCollection 2012.


Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE.

Clin Cancer Res. 2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14.


PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells.

Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR.

PPAR Res. 2011;2011:171765. doi: 10.1155/2011/171765. Epub 2011 Dec 12.


Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology.

Schweppe RE, Haugen BR.

Thyroid. 2011 Sep;21(9):941-4. doi: 10.1089/thy.2011.2109.ed. No abstract available.


Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion.

Bauerle KT, Schweppe RE, Haugen BR.

Mol Cancer. 2010 May 21;9:117. doi: 10.1186/1476-4598-9-117.


Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells.

Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.

Endocr Rev. 2009 Dec 1;30(7):932. doi: 10.1210/edrv.30.7.9986. No abstract available.


Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.

J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. doi: 10.1210/jc.2009-0373. Epub 2009 Oct 30.


Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR.

Thyroid. 2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362.


Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.

Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG.

Mol Cell. 2009 Apr 10;34(1):115-31. doi: 10.1016/j.molcel.2009.03.007.


Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.

Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR.

J Clin Endocrinol Metab. 2009 Jun;94(6):2199-203. doi: 10.1210/jc.2008-2511. Epub 2009 Mar 17.


Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR.

J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41. doi: 10.1210/jc.2008-1102. Epub 2008 Aug 19.


Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses.

Schweppe RE, Cheung TH, Ahn NG.

J Biol Chem. 2006 Jul 28;281(30):20993-1003. Epub 2006 May 30.


The characterization of protein post-translational modifications by mass spectrometry.

Schweppe RE, Haydon CE, Lewis TS, Resing KA, Ahn NG.

Acc Chem Res. 2003 Jun;36(6):453-61. Review.


Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells.

Tentler JJ, Bradford AP, Schweppe RE, Gutierrez-Hartmann A.

Endocrine. 2003 Feb-Mar;20(1-2):3-12.


Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter.

Schweppe RE, Melton AA, Brodsky KS, Aveline LD, Resing KA, Ahn NG, Gutierrez-Hartmann A.

J Biol Chem. 2003 May 9;278(19):16863-72. Epub 2003 Mar 4.


Monitoring post-translational modification of proteins with allosteric ribozymes.

Vaish NK, Dong F, Andrews L, Schweppe RE, Ahn NG, Blatt L, Seiwert SD.

Nat Biotechnol. 2002 Aug;20(8):810-5. Epub 2002 Jul 15.


Fibroblast growth factor activation of the rat PRL promoter is mediated by PKCdelta.

Jackson TA, Schweppe RE, Koterwas DM, Bradford AP.

Mol Endocrinol. 2001 Sep;15(9):1517-28.


Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter.

Schweppe RE, Gutierrez-Hartmann A.

Nucleic Acids Res. 2001 Mar 1;29(5):1251-60.


Phosphorylation of B-Myb regulates its transactivation potential and DNA binding.

Johnson TK, Schweppe RE, Septer J, Lewis RE.

J Biol Chem. 1999 Dec 17;274(51):36741-9.


Supplemental Content

Loading ...
Support Center